Clinicopathological characteristics, prognostic factors, and outcomes of elderly patients with lymphoma‐associated hemophagocytic lymphohistiocytosis: A multicenter analysis
Open Access
- 1 August 2024
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 13 (16) , e70178
Abstract
Background: Lymphoma is the most common secondary cause of hemophagocytic lymphohistiocytosis (HLH) in adults. Lymphoma‐associated HLH (LA‐HLH) in the elderly population is not rare, however, little has been reported regarding clinicopathological characteristics, prognostic factors, and outcomes of LA‐HLH in the elderly population.Methods: We retrospectively analyzed a multicenter cohort of elderly patients with LA‐HLH. Clinicopathological features and treatment information were collected. The impacts of baseline characteristics and treatments on survival outcomes were analyzed.Results: A total of 173 elderly patients with LA‐HLH were included. Compared with young patients, elderly patients showed different clinical and laboratory features. Regarding lymphoma subtypes, B‐cell lymphoma was more common in elderly patients (elderly 61.3% vs. young 32.3%, p < 0.001) while T/NK‐cell lymphoma was more common in young patients (65.3% vs. 35.3%, p < 0.001). The median survival of elderly patients with LA‐HLH was only 92 days. The prior use of HLH therapy or etoposide‐containing HLH therapy was not associated with improved overall survival. T/NK‐cell subtype, a lower platelet count (≤53 × 109/L), a lower albumin level (≤32.1 g/L), a higher LDH level (>1407 U/L), and a higher creatinine level (>96.8 μmol/L) were independent predictors of decreased overall survival and 60‐day survival. A prognostic index was established and demonstrated to be robust in predicting the overall survival and 60‐day survival of elderly patients with LA‐HLH.Conclusions: LA‐HLH in elderly patients displayed heterogeneous clinicopathological features and survival outcomes. Treatments need to be optimized to improve the outcomes of elderly patients with LA‐HLH.Keywords
Funding Information
- Natural Science Foundation of Jiangsu Province (BK20210962)
This publication has 31 references indexed in Scilit:
- Serum sCD25/ferritin ratio combined with MCP-1 is a valid predictor for identifying LAHS with HLH as the first manifestationJournal of Cancer Research and Clinical Oncology, 2023
- The Clinical Significance and Prognostic Role of Whole-Blood Epstein-Barr Virus DNA in Lymphoma-Associated Hemophagocytic LymphohistiocytosisJournal of Clinical Immunology, 2023
- The emerging role of anti-PD-1 antibody-based regimens in the treatment of extranodal NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosisJournal of Cancer Research and Clinical Oncology, 2022
- Malignancy-associated haemophagocytic lymphohistiocytosisThe Lancet Haematology, 2022
- Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCLCancer Cell, 2021
- Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registryJournal of Cancer Research and Clinical Oncology, 2020
- Natural Killer/T-cell Neoplasms: Analysis of Incidence, Patient Characteristics, and Survival Outcomes in the United StatesClinical Lymphoma Myeloma and Leukemia, 2018
- Adult haemophagocytic syndromeThe Lancet, 2014
- Presentation and management of intravascular large B-cell lymphomaThe Lancet Oncology, 2009
- HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosisPediatric Blood & Cancer, 2006